Skip to main
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is a pharmaceutical company that faces slow growth and risks, like drug pricing pressures and changes in reimbursement models, but differentiates themselves through diverse services and partnerships with specialty practices. The company is investing in expansion and returning capital to shareholders, and has a revised long-term outlook for growth in revenue and adjusted EPS. Additionally, they have a strong infrastructure and unique focus on radiopharmaceuticals which could provide potential profits from biosimilars in 2028.

Bears say

Cardinal Health is poised for growth in the pharmaceutical distribution industry due to favorable market conditions and strategic initiatives, but potential risks such as regulatory issues and changes in drug policies could impact their profitability. The company's focus on providing specialty products and expanding customer base through strategic partnerships could mitigate these risks, but it remains to be seen how effectively they can navigate the challenging landscape. However, a negative outlook is warranted due to potential challenges and uncertainties that could impact Cardinal Health in the future.

Cardinal Health (CAH) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 12 analysts, Cardinal Health (CAH) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.